Therapeutic area

Immune system disorders – page 72

1 664 clinical trials
562 recruiting
293 conditions
29 countries

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Click a country to filter the trials

Quick filters

1 664 clinical trials

Primary biliary cholangitis

Not recruiting

Study of Elafibranor in Adults with Primary Biliary Cholangitis Who Don't Respond Well to or Cannot Tolerate Ursodeoxycholic Acid Treatment

Investigational

Study of Elafibranor in Adults with Primary Biliary Cholangitis Who Don't Respond Well to or Cannot Tolerate Ursodeoxycholic Acid Treatment

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Elafibranor
Sponsor:Ipsen Bioscience Inc.

Contact Research Centre

Systemic scleroderma

Not recruiting

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

InvestigationalNo placebo

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Fipaxalparant
Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Contact Research Centre

Colitis ulcerative

Not recruiting

Study of Tulisokibart for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo

Study of Tulisokibart for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Tulisokibart
Sponsor:Prometheus Biosciences Inc.

Contact Research Centre

Asthma

Not recruiting

Study of dupilumab added to inhaled corticosteroids and long-acting beta-agonists compared to high-dose inhaled therapy in adolescents and adults with uncontrolled asthma

Registered drug

Study of dupilumab added to inhaled corticosteroids and long-acting beta-agonists compared to high-dose inhaled therapy in adolescents and adults with uncontrolled asthma

Registered drug

Denmark

Participants:0–17 years · 18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Study of Obexelimab Treatment for Adults with Systemic Lupus Erythematosus (SLE)

Registered drug

Study of Obexelimab Treatment for Adults with Systemic Lupus Erythematosus (SLE)

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Obexelimab
Sponsor:Zenas Biopharma (USA) LLC

Contact Research Centre

Chronic spontaneous urticaria

Not recruiting

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Barzolvolimab
Sponsor:Celldex Therapeutics Inc.

Contact Research Centre

Rheumatoid arthritis

Not recruiting

Study on the Effects of AP1189 and Methotrexate for Patients with Early Rheumatoid Arthritis and Active Inflammation

Registered drug

Study on the Effects of AP1189 and Methotrexate for Patients with Early Rheumatoid Arthritis and Active Inflammation

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Methotrexate
Sponsor:Synact Pharma ApS

Contact Research Centre

Cardiac amyloidosis

Not recruiting

Study of Vutrisiran for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug

Study of Vutrisiran for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Vutrisiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Chronic spontaneous urticaria

Not recruiting

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Barzolvolimab
Sponsor:Celldex Therapeutics Inc.

Contact Research Centre

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of Vibozilimod for Adults with Moderate to Severe Plaque Psoriasis

Investigational

Study on the Effectiveness and Safety of Vibozilimod for Adults with Moderate to Severe Plaque Psoriasis

Investigational

Estonia

Participants:18–64 years · 65+ years
Substances:Vibozilimod
Sponsor:Sun Pharmaceutical Industries Limited

Contact Research Centre

Psoriatic arthropathy

Not recruiting

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

Investigational

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Risankizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on the Effects of GSK1070806 Injection in Adults with Moderate to Severe Atopic Dermatitis

Investigational

Study on the Effects of GSK1070806 Injection in Adults with Moderate to Severe Atopic Dermatitis

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Humanised IgG1 kappa monoclonal antibody against interleukin 18
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trials Rituximab50 clinical trials Prednisone47 clinical trials Adalimumab40 clinical trials Emtricitabine40 clinical trials Tenofovir Alafenamide38 clinical trials Tocilizumab38 clinical trials Methotrexate37 clinical trials Prednisolone35 clinical trials

Immune system disorders – page 72

Conditions in this area

Clinical trials in Immune system disorders

1 664 clinical trials

Primary biliary cholangitis

Study of Elafibranor in Adults with Primary Biliary Cholangitis Who Don't Respond Well to or Cannot Tolerate Ursodeoxycholic Acid Treatment

Systemic scleroderma

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

Colitis ulcerative

Study of Tulisokibart for Patients with Moderately to Severely Active Ulcerative Colitis

Asthma

Study of dupilumab added to inhaled corticosteroids and long-acting beta-agonists compared to high-dose inhaled therapy in adolescents and adults with uncontrolled asthma

Systemic lupus erythematosus

Study of Obexelimab Treatment for Adults with Systemic Lupus Erythematosus (SLE)

Chronic spontaneous urticaria

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Rheumatoid arthritis

Study on the Effects of AP1189 and Methotrexate for Patients with Early Rheumatoid Arthritis and Active Inflammation

Cardiac amyloidosis

Study of Vutrisiran for Patients with Transthyretin Amyloidosis and Heart Disease

Chronic spontaneous urticaria

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Psoriasis

Study on the Effectiveness and Safety of Vibozilimod for Adults with Moderate to Severe Plaque Psoriasis

Psoriatic arthropathy

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

Dermatitis atopic

Study on the Effects of GSK1070806 Injection in Adults with Moderate to Severe Atopic Dermatitis

Filter the trials

Substances studied in this area

Prefer not to search? Our Concierge searches the trials for you.